Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit

PJ Van Leeuwen, D Connolly, A Gavin… - European Journal of …, 2010 - Elsevier
BACKGROUND: To estimate the benefits of prostate-specific antigen (PSA) screening on
prostate cancer (Pca) metastasis and Pca-specific mortality, we compared two populations …
被引用次数：91 相关文章

Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.

PJ van Leeuwen, D Connolly, A Gavin… - European Journal of …, 2009 - europepmc.org
Background To estimate the benefits of prostate-specific antigen (PSA) screening on
prostate cancer (Pca) metastasis and Pca-specific mortality, we compared two populations …

Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefit.

PJ Van Leeuwen, D Connolly, A Gavin… - European Journal of …, 2010 - pure.qub.ac.uk
Background To estimate the benefits of prostate-specific antigen (PSA) screening on
prostate cancer (Pca) metastasis and Pca-specific mortality, we compared two populations …
[PDF] academia.edu

[PDF][PDF] Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefit

PJ van Leeuwen, D Connolly, A Gavin… - EUROPEAN …, 2010 - academia.edu
Background: To estimate the benefits of prostate-specific antigen (PSA) screening on
prostate cancer (Pca) metastasis and Pca-specific mortality, we compared two populations …

[引用][C] Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefit

PJ VAN LEEUWEN, D CONNOLLY… - European journal of …, 2010 - pascal-francis.inist.fr
Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the
screening benefit CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic …

Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.

PJ Leeuwen, D Connolly, A Gavin, MJ Roobol, A Black… - 2010 - cabidigitallibrary.org
Background: To estimate the benefits of prostate-specific antigen (PSA) screening on
prostate cancer (Pca) metastasis and Pca-specific mortality, we compared two populations …

Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefit

PJ van Leeuwen, D Connolly, A Gavin… - European Journal of …, 2010 - ejcancer.com
Background To estimate the benefits of prostate-specific antigen (PSA) screening on
prostate cancer (Pca) metastasis and Pca-specific mortality, we compared two populations …
[PDF] core.ac.uk

[PDF][PDF] Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefit.

PJ Van Leeuwen, D Connolly, A Gavin… - European journal of …, 2010 - core.ac.uk
Background: To estimate the benefits of prostate-specific antigen (PSA) screening on
prostate cancer (Pca) metastasis and Pca-specific mortality, we compared two populations …
[PDF] eur.nl

[PDF][PDF] Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefit

PJ van Leeuwen, D Connolly, A Gavin… - Prostate Cancer …, 2010 - repub.eur.nl
Methods: Between 1997 and 1999, a total of 11,970 men, aged 55-74 years, were included
in the intervention arm of the European Randomized Study of Screening for Prostate Cancer …

Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit

PJ van Leeuwen, D Connolly, A Gavin, MJ Roobol… - 2010 - pubmed.ncbi.nlm.nih.gov
Background To estimate the benefits of prostate-specific antigen (PSA) screening on
prostate cancer (Pca) metastasis and Pca-specific mortality, we compared two populations …